100,291 Shares in Bicycle Therapeutics PLC Sponsored ADR $BCYC Acquired by Janney Montgomery Scott LLC

Key Points

• Janney Montgomery Scott LLC acquired 100,291 shares of Bicycle Therapeutics PLC, valued at approximately $697,000, during the 2nd quarter, representing about 0.14% of the company.
• The company's stock has a fifty-two week range of $6.10 to $28.67, with a current market cap of $581.51 million.
• Following the most recent earnings report, Bicycle Therapeutics posted a loss of ($1.14) EPS, missing analysts' expectations, and they are projected to post -3.06 EPS for the current year.

Janney Montgomery Scott LLC acquired a new position in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 100,291 shares of the company's stock, valued at approximately $697,000. Janney Montgomery Scott LLC owned about 0.14% of Bicycle Therapeutics at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC bought a new position in shares of Bicycle Therapeutics in the first quarter worth approximately $1,065,000. Principal Financial Group Inc. boosted its stake in Bicycle Therapeutics by 55.3% in the first quarter. Principal Financial Group Inc. now owns 631,260 shares of the company's stock worth $5,359,000 after buying an additional 224,790 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in Bicycle Therapeutics by 90.3% in the first quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after buying an additional 6,057 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in Bicycle Therapeutics in the first quarter worth approximately $214,000. Finally, Westfield Capital Management Co. LP boosted its stake in Bicycle Therapeutics by 1.8% in the first quarter. Westfield Capital Management Co. LP now owns 2,657,305 shares of the company's stock worth $22,561,000 after buying an additional 46,968 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Kevin Lee sold 3,231 shares of the firm's stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $8.41, for a total value of $27,172.71. Following the completion of the sale, the chief executive officer owned 475,310 shares of the company's stock, valued at $3,997,357.10. This trade represents a 0.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 8,527 shares of company stock valued at $71,738 over the last ninety days. Company insiders own 22.90% of the company's stock.

Wall Street Analyst Weigh In

BCYC has been the subject of several research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Bicycle Therapeutics in a research note on Tuesday. Morgan Stanley cut their target price on Bicycle Therapeutics from $17.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, August 12th. JMP Securities cut their target price on Bicycle Therapeutics from $22.00 to $10.00 and set a "market outperform" rating for the company in a research note on Tuesday, August 12th. Royal Bank Of Canada set a $27.00 target price on Bicycle Therapeutics and gave the stock an "outperform" rating in a research note on Monday, August 11th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $44.00 target price (down previously from $48.00) on shares of Bicycle Therapeutics in a research note on Monday, August 11th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $22.22.

Bicycle Therapeutics Stock Performance

NASDAQ:BCYC opened at $8.39 on Thursday. The firm has a market cap of $581.51 million, a PE ratio of -2.39 and a beta of 1.47. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $6.10 and a fifty-two week high of $28.67. The business has a 50 day moving average price of $7.45 and a 200-day moving average price of $7.78.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($0.95) by ($0.19). Bicycle Therapeutics had a negative return on equity of 32.43% and a negative net margin of 1,257.00%.The business had revenue of $2.90 million during the quarter, compared to analysts' expectations of $9.43 million. Research analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.